New York, April 25, 2019 With years of exploration in antibody engineering, Creative Biolabs recently has built a full-scale in silico technology platform to offer high quality antibody developability prediction services for customers all over the world, including Antibody Aggregation Prediction and Antibody Immunogenicity prediction.
In order to evaluate the possibility for the successful development of a lead candidate into a stable, safe, manufacturable, and efficacious drug, a variety of in silico analysis approaches are provided at an early stage of drug development by Creative Biolabs, including N-Glycosylation Sites and Cysteines in Fv Domains Analysis, Lysine Glycation Sites Analysis, Isoelectric Point and Charge Distribution Analysis, Prediction of Asparagine and Aspartate Degradation Hotspots in Fv Domains Analysis, Immunogenicity Analysis.
For antibody protein aggregation, increasing the intrinsic properties of antibodies can promote manufacturability, attrition rates, formulation, safety, titers, immunogenicity, and solubility. The identification of aggregation-prone regions enables to predict and decrease the aggregation propensity of monoclonal antibodies.
In Creative Biolabs, the empirical force field FoldX is offered to measure thermodynamic stability, which can remove the free energy of folding of protein structure by combining the local contributions of all residues. Meanwhile, the statistical thermodynamic algorithm TANGO is used to evaluate the presence of APRs by measuring the intrinsic aggregation propensity of APRs as a Boltzmann distribution with competing secondary structural tendencies, for example, α-helical or β-hairpin structure, characterized by well-defined sequence boundaries and high specificity with few false-positive APRs.
“Based our well-established in silico technology platform, we also offer there epitope prediction methods, which are T-cell epitope prediction, B-cell epitope prediction, De-immunization, to accurately evaluate proteins and measure the regional and overall immune potential of a protein therapeutic. Our EpiMatrix method can illustrate the basic process of screening a protein therapeutic for immunogenicity. And 3DEX and CEP, B-cell epitope prediction tools, are able to be used to predict B-cell epitopes on a high-throughput basis.” Introduced by the manager in Creative Biolabs.
Besides, with the comprehensive antibody developability prediction services, it is available to design and engineer novel antibodies with desired therapeutic properties in Creative Biolabs. The service can be customized according to the specific requirements from customers. More information can be reached at https://www.creative-biolabs.com/preciab.
Creative Biolabs was founded by scientists who are dedicated to the conquering of cancer, believing that a custom-service-centered business model is important for optimizing the drug development process, leveraging accessible resources, and forming a team of various background to conduct drug discovery in future. The service portfolio includes mouse and rat monoclonal antibody production using hybridoma technology, human, monkey, rabbit, chicken, dog, llama and camel monoclonal antibody production using various antibody library technologies (including phage display, bacterial display and yeast display). In addition, OEM services for bulk scale antibody manufacturing, including bacterial production of scFv, diabody, tandem scFv, miniantibody and Fab, and mammalian cell expression of minibody, chimeric IgG and IgG, are also available at the most competitive price in the industry.
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Address:45-1 Ramsey Road
State: New York
Country: United States